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S6 Abstractsinfluenza virus (HPAIV) strain H5N1 has resulted in serious economic losses to the poultry industry, many countries including Vietnam have
introduced mass vaccination of poultry with H5N1 virus vaccines. We found that eggs obtained from chicken farms and supermarkets in Vietnam
contain H5N1-specific immunoglobulins (IgY) that provide protection against infections with HPAIV H5N1 and related H5N2 strains in mice.
When administered intranasally before or after lethal infection with HPAIV H5N1, H5N1-specific IgY prevent disease or significantly reduce viral
replication resulting in complete recovery from the disease, respectively. In addition, we generated H1N1 virusspecific IgY by immunization of hens
with inactivated H1N1 A/PR/8/34 as a model virus for current pandemic H1N1/09 and found that such H1N1-specific IgY protect mice from lethal
influenza virus infection.
These results underscore the usefulness of recombinant Ad vectors encoding surface glycoprotein (HA) and conserved protein (M2e) and NS1
deleted viruses (DelNS1) as vaccine candidates for control of pre-pandemic H5N1 and newly emerging subtypes. Data on antiviral efficacy of IgY
provide a proof-of-concept for the approach using virus-specific IgY as affordable, safe, and effective alternative for the control of influenza
outbreaks, including the potential H5N1 and current H1N1 pandemic.
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In response to the global spread of the H1N1 influenza virus after first being detected in North America in April 2009, WHO declared the first
influenza pandemic in more than four decades on June 11 of the same year. In Korea, the arrival of the 2009 H1N1 pandemic influenza triggered an
integrated response that was mainly based on the 2006 Pandemic Influenza Preparedness and Response Plan. At least 270 fatal cases, 764
laboratory-thousand confirmed cases, and 3.6 million courses of antiviral agent use were reported to the end of August 2010 in this country. Even if
government tried to control and mitigate the impact of pandemic by using public health and medical countermeasures, there were several issues
found during the H1N1 pandemic responses. The main difficulty was the delayed and insufficient supply of pandemic vaccine. Therefore the mass
vaccination campaign was begun after the peak of pandemic and its mitigation effect on the pandemic disease burden was diminished. The amount
of stockpiled antiviral agents by government was not enough in the early phase of pandemic. The rapid antigen test for the H1N1 influenza showed
low sensitivity, about 50%. Many infected people were seeking to be diagnosed with rRT-PCR test, which is expensive and not useful for the
decision of antiviral use because of late test report. The communications among government, medical societies, general people and mass media were
also not satisfactory. Lessons learned from the national response to the H1N1 pandemic made the government to launch the TEPIK in October 2010.
TEPIK will incorporate those lessons into the future pandemic preparedness planning. The mission of TEPIK is to ensure the safety of the nation
and people from the threat of pandemic influenza. TEPIK focuses to establish government-academic-institute-industry collaborative system with
three main strategies; to expedite sharing of R&D information and preparation of national communication; to establish the preparedness and
response of R&D investment strategy for usual and pandemic phase; and to secure the innovative and leading response technology against pandemic
influenza. TEPIK has 34 research projects in eight research areas, which include vaccine; therapeutics; diagnostics; basic/mechanism; clinical/
policy; surveillance/epidemiology; innovative researches; and infrastructures. Research subjects in each research area will be stated in this
presentation.
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Until 2000 when the Communicable Diseases Control Law was revised, influenza has been considered as one of the neglected disease in Korea. The
vaccine coverage was low and there were no reliable statistics about influenza. With the revision of the Law, influenza was grouped as group III
disease which needs surveillance and Korea Influenza Surveillance Scheme (KISS) was launched on September of 2000.
While the surveillance system has been established and improved with following seasons, diagnosis and related research has been diversified and
intensified. With the successive outbreak of SARS and avian influenza outbreaks from 2003, 2006, 2008 and 2010, diagnosis of influenza has been
improved by the introduction of genetic detection from RT-PCR to multiplex RT-PCR. During the 2009 pandemic we introduced the multiplex
realtime RT-PCR and it is being used now which can differentiate seasonal influenza (H1, H3 and B), A(H1N1)pdm09, and H5. For the serological
diagnosis, conventional hemagglutination inhibition and microneutralization has been established with standardization for each virus using various
red blood cell or variation of HA antigen preparation. Also to minimize the possible infection by highly pathogenic avian influenza virus (HPAIV),
microneutralization using pseudotype virus with appropriate HA gene of HPAIV has been developed.
Also with the increased the need for molecular analysis based on sequence, Influenza Sequence and Epitope Database (ISED) was developed in
2008 and expanded the contents from seasonal influenza to avian influenza with various hosts. The result of genetic characterization to detect the
variation in antigenic sites and antiviral drugs resistance has been widely used for the surveillance and also for the treatment of influenza patients
since the worldwide spread of drug resistant virus.
